Sugi Predict

Sugi Predict / Compounds / SCHEMBL2079

SCHEMBL2079

SCHEMBL2079

CCOC(=O)C1(CN)CCCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ POLB P06746 3/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ CYP4F2 P78329 1/20 0.36
▸ CYP4A11 Q02928 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ GAA P10253 1/20 0.35
▸ OPRM1 P35372 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ LMNA P02545 2/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ USP2 O75604 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ BLM P54132 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16838736 0.98 CYP1A2 (0.38) CYP1A2SMN1; SMN2ALOX15POLBKDM4E
SCHEMBL2123 0.98 CYP1A2 (0.38) CYP1A2SMN1; SMN2ALOX15POLBKDM4E
Hydrochloric Acid SCHEMBL5616975 0.96 CYP1A2 (0.37) CYP1A2SMN1; SMN2ALOX15POLBKDM4E
SCHEMBL425037 0.96 SMN1; SMN2 (0.41) CYP1A2SMN1; SMN2ALOX15POLBKDM4E
Hydrochloric Acid SCHEMBL5616928 0.94 SMN1; SMN2 (0.41) CYP1A2SMN1; SMN2ALOX15POLBKDM4E
SCHEMBL1161503 0.92 CYP1A2 (0.42) CYP1A2SMN1; SMN2ALOX15POLBMEN1
Hydrochloric Acid SCHEMBL1141219 0.90 CYP1A2 (0.41) CYP1A2SMN1; SMN2ALOX15POLBALDH1A1
SCHEMBL17454 0.83 SMN1; SMN2 (0.40) SMN1; SMN2ALOX15POLBKDM4EMEN1
SCHEMBL19415396 0.83 TSHR (0.37) CYP1A2SMN1; SMN2POLBMEN1KMT2A
SCHEMBL390562 0.83 OPRM1 (0.49) CYP1A2SMN1; SMN2ALOX15POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179075-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-06-05 — — US disclosed
US-20250163074-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2025-05-22 — — US disclosed
US-12129262-B2 CDK inhibitors and their use as pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED (US) 2024-10-29 — — US disclosed
EP-4448493-A1 PICOLINAMIDE COMPOUNDS AS SELECTIVE PHD1 INHIBITORS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics, Inc. (US) 2024-10-23 — — EP disclosed
US-20240327376-A1 PICOLINAMIDE COMPOUNDS AS SELECTIVE PHD1 INHIBITORS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2024-10-03 — — US disclosed
CN-116940563-A CDK inhibitors and their use as pharmaceuticals 普莱鲁德疗法有限公司 2023-10-24 — — CN disclosed
WO-2023111985-A1 PICOLINAMIDE COMPOUNDS AS SELECTIVE PHD1 INHIBITORS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-06-22 — — WO disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 — — US disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 — — US disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 — — US disclosed
US-5646143-A FOR TREATING A VARIETY OF CONDITIONS CIBA-GEIGY CORPORATION (US) 1997-07-08 — — US disclosed
US-5627182-A RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS CIBA GEIGY CORPORATION (US) 1997-05-06 — — US disclosed
US-5620998-A CARDIOVASCULAR DISORDERS; HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1997-04-15 — — US disclosed
US-5559233-A 3-/P-PHENYLBENZYL/IMIDAZOLONES AND PYRIMIDONES SANOFI (FR) 1996-09-24 — — US disclosed
US-5559111-A HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren CIBA-GEIGY CORPORATION (US) 1996-09-24 — — US disclosed
WO-1996026183-A1 1-ARYL-2-ACYLAMINO-ETHANE COMPOUNDS AND THEIR USE AS NEUROKININ ESPECIALLY NEUROKININ 1 ANTAGONISTS NOVARTIS AG (CH) 1996-08-29 — — WO disclosed
US-5506240-A HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1996-04-09 — — US disclosed
US-5399578-A Hypotensive; valsartan; high blood pressure and cardiac insufficiency CIBA-GEIGY CORP (US) 1995-03-21 — — US disclosed
US-5352788-A Angiotensin antagonist ELF SANOFI (FR) 1994-10-04 — — US disclosed
US-5270317-A N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present ELF SANOFI (FR) 1993-12-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF MKNK2, MKRN3, DUS2 CYP1A2 74/4885SMN1; SMN2 3385/4885ALOX15 2519/4885
US-20250163074-A1 CDK Inhibitors And Their Use As Pharmaceuticals CDK6, CDK1, CDK3 CYP1A2 1443/4885SMN1; SMN2 1955/4885ALOX15 3743/4885
US-20240327376-A1 PICOLINAMIDE COMPOUNDS AS SELECTIVE PHD1 INHIBITORS, COMPOSITIONS, AND METHODS OF USE EGLN2, EGLN3, HIF1AN CYP1A2 1376/4885SMN1; SMN2 2564/4885ALOX15 1939/4885
US-12129262-B2 CDK inhibitors and their use as pharmaceuticals CDK6, CDK1, CDK3 CYP1A2 1443/4885SMN1; SMN2 1955/4885ALOX15 3743/4885
US-20250179075-A1 MK2 DEGRADERS AND USES THEREOF MKNK2, MKRN3, DUS2 CYP1A2 74/4885SMN1; SMN2 3385/4885ALOX15 2519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.